Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03600831 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 434 | Huai'an First People's HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 |
| clinicaltrials |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 235 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01394263 | Study of Histrelin Subdermal Implant in Patients With Prostate Cancer | completed | Phase 3 | 59 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT01697384 | Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer | completed | Phase 3 | 138 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | unknown | Phase 3 | 194 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06146777 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | not yet recruiting | Phase 3 | 468 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT04187352 | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 540 | CStone PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05197257 | 68Ga-PSMA-11 PET in Patients With Prostate Cancer | completed | Phase 3 | 39 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | completed | Phase 3 | 746 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Oct 24, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT01949337 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | unknown | Phase 3 | 1,311 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 28, 2023 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy(POLO) | completed | Phase 3 | 154 | AstraZenecaINDUSTRY | 12 | Sep 13, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06016400 | Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma | unknown | Phase 2 / Phase 3 | 412 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05985187 | Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. | unknown | Phase 3 | 412 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05623267 | Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT(SURPASS) | recruiting | Phase 2 / Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy(IMmotion010) | terminated | Phase 3 | 778 | Hoffmann-La RocheINDUSTRY | 28 | Aug 3, 2023 | clinicaltrials |
| NCT03790553 | Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma | unknown | Phase 3 | 646 | Fudan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT04914195 | Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer | completed | Phase 3 | 155 | Bharat Serums and Vaccines LimitedINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02763579 | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)(IMpower133) | completed | Phase 3 | 503 | Hoffmann-La RocheINDUSTRY | 21 | Jul 28, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02627963 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | completed | Phase 3 | 350 | AVEO Pharmaceuticals, Inc.INDUSTRY | 12 | Jul 18, 2023 | clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05263219 | DEB-TACE+HAIC vs. HAIC for Large HCC | unknown | Phase 3 | 230 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02973685 | HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | completed | Phase 3 | 315 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2024source: clinicaltrials